DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR MS Speaks
       *****************************************************
   DIR (JAMA) 3rd dose of mRNA COVID-19 vaccine in MS patients treate...
       0 replies
   DIR (Abst.) Mild PML after switching from Tysabri to Ocrevus
       0 replies
   DIR (Abst.) Clinical outcomes of patients w/MS treated w/Ocrevus...
       1 replies
   DIR (Abst.) Are disease-modifying drugs for progressive MS worthwh...
       0 replies
   DIR Immune-suppressed patients in Ontario eligible for earlier COV...
       0 replies
   DIR Higher severe COVID-19 risk for patients on Ocrevus, Rituxan
       1 replies
   DIR Fatal PML case in 78-year-old patient on Ocrevus monotherapy
       3 replies
   DIR (Abst.) Ocrelizumab depletes T-lymphocytes more than rituximab...
       0 replies
   DIR (Abst.) Shorter infusion time of ocrelizumab...
       1 replies
   DIR (ACTRIMS/ECTRIMS) Some MS drugs linked with worse COVID-19 out...
       0 replies
       *****************************************************
       Page 4 of 10
   DIR Previous Page
   DIR Next Page